Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma

Table 1 Comparison of general information (mean ± SD)

Project	Observation group (n = 50)	Control group (n = 50)	χ2/t	P value
Gender, n (%)
Male	21 (42.00)	28 (64.00)	1.961	0.161
Female	29 (58.00)	22 (36.00)
Age (years), mean ± SD	57.84 ± 6.37	56.49 ± 6.15	1.007	0.316
Hepatitis B virus positive, n (%)	45 (90.00)	47 (94.00)	0.543	0.461
Cirrhosis, n (%)	36 (72.00)	39 (78.00)	0.480	0.488
Tumor length (cm), n (%)
≥ 5	37 (74.00)	39 (78.00)	0.219	0.640
< 5	13 (26.00)	11 (22.00)
Multiple tumors, n (%)	7 (14.00)	9 (18.00)	0.298	0.585
TNM staging, n (%)
Stage I to II	19 (38.00)	15 (30.00)	0.713	0.398
Stage III	31 (62.00)	35 (70.00)
Child-Pugh liver function grade, n (%)
A-level	23 (46.00)	20 (40.00)	0.545	0.367
Class B	27 (54.00)	30 (60.00)
Physical activity status score, n (%)
0	29 (58.00)	32 (66.00)	0.378	0.539
1	21 (42.00)	18 (34.00)